DOCSLIB.ORG

Px Code Procedure Description Unit Price 11000001 Room & Board

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Px Code Procedure Description Unit Price 11000001 Room & Board Px Code Procedure Description Unit Price 11000001 Room & Board - Private General $1,931.00 11200001 ROOM & BOARD - OB PRIVATE $1,931.00 11300001 Room & Board - Private Pediatric $1,931.00 11400001 ROOM & BOARD - BHU $3,097.00 11600001 ROOM & BOARD - CHEM DEP $4,142.00 11800001 ROOM & BOARD - REHAB $1,931.00 11800002 ROOM & BOARD - IP REHAB $2,301.00 16400001 ROOM & BOARD - ISOLATION $2,225.70 16400002 ROOM & BOARD - PCU ISOLATION $3,390.00 17100001 Nursery Newborn - Level I $1,936.00 17200001 Nursery Newborn - Level II $4,583.00 17300003 Nursery Newborn - Level III $5,941.00 17900001 ROOM & BOARD - SICK BABY LVL 1 $2,382.00 17900002 ROOM & BOARD - HEALTHY BOARDER $2,382.00 18000001 HB LEAVE OF ABSENCE (LOA) $0.01 20000001 Intensive Care General $4,851.00 20600001 Post ICU (AKA Intermediate) $4,123.21 20600004 ROOM & BOARD - TELEMETRY PCU $2,225.70 20600005 ROOM & BOARD - PCU PRIVATE $4,123.00 20600006 ROOM & BOARD - CARDIAC CARE MED SURG $1,931.00 20600007 ROOM & BOARD - CARDIAC CARE TELEMETRY $2,550.00 21000001 HB CORONARY CARE GENERAL $4,851.00 25000001 HB RX 250-PHARMACY $602.48 25000012 HB SOLUTION BAX 5B9896 4.25%2000M $96.66 25000013 HB SOLUTION BAX 5B9866 1.5%2000ML $86.52 25500001 HB RX 255-DRUGS INCIDENT TO RADIOLOGY $5,715.25 25800001 HB RX 343-DX RADIOPHARM $678.82 26000001 HB ADMIN IV HYDRATE; EA ADDTL HR $283.00 26000002 HB ADMIN IV INF TX/DX; 1ST HR $1,045.50 26000003 HB ADMIN IV INF TX/DX; EA ADDTL HR $376.00 26000004 HB ADMIN IV INF TX/DX; EA SEQUENTI $547.50 26000005 HB ADMIN IV INF TX/DX; CONCURRENT $778.50 26000006 HB ADMIN IV PUSH TX/DX; EA NEW MED $440.50 26000007 HB ADMIN IV PUSH; EA ADDTL SAME DRUG SEQ $440.50 26000008 HB ADMIN IV HYDRATE; 1ST HOUR $1,049.00 26000010 HB ADMIN IV PUSH TX/DX; 1ST MED $479.50 26000011 HB ADMIN INJ IM/SUBQ TX/DX MED $329.00 26000013 HB IRRIGATE VAD (FLUSH PORT/PICC) $367.50 26000015 HB APPLICATION OF ON-BODY INJECTOR $128.00 26000017 HB ADMIN SQ INFUSION; 1ST HOUR $1,019.50 26000018 HB ADMIN SQ INFUSION; EA ADDL HR $300.00 26000019 HB ADMIN ADD SQ INF; NEW SITE $412.50 27000004 HB COMPRESSED AIR $170.00 27000484 HB STAPLER ETH PRW35 $200.00 27000641 HB CARTRIDGE VAP PF-DPC-LOW $261.00 27000710 HB PACK C-SEC PB2235659 $2.00 27000727 HB PLEUR-EVAC MAQ 3600-100 CHEST DRAIN $93.75 27000728 HB PACK VAG PB3235659B $2.00 27000740 HB PACK LABOR PB1235659 $2.00 27000751 HB OXYGEN 02/SUPPLEMENTAL $725.00 27040684 HB CATHETER SET RE-ENTRY NEPHROS $286.37 27040765 HB MYOSURE XL $500.00 27040927 HB DAILY OXYGEN CHARGE $725.00 27045040 HB SHUNT MAQ OF-1500L LNG STD 20.25MM 16.25MM $235.00 27140004 HB OXYGEN PER SHIFT $362.50 27200209 HB SUTURE ARX AR-7230-01 $66.00 27200578 HB BUR WRI ALL 57SXXXX $1,770.00 27200754 HB VIPERSLIDE CSI VPR-SLD LUBRICT $252.00 27200772 HB CATH COR 426-2022X SLEEK $858.00 27200947 HB CATH TER 40-5023 $115.50 27200953 HB STAPLER CAR ESPRR35 SKIN $52.94 27200956 HB INTRODUCER GOR DSF2233 DRYSEAL FLEX $420.00 27200975 HB CATH BOS ALL H74939189XXXXX EMERGE PTCA DILATION $560.00 27201339 HB CATH EV3 ALL 410XX-01 CRAGG-MCNAMARA $420.00 27201728 HB SCD SLEEVE THIGH REGULAR $90.00 27201840 HB TROCAR APP CFF03/CFR03 $270.00 27201971 HB INTRODUCER MMD ALL CLS-10XX (31.93) $103.23 27202016 HB LIGASURE COV LF1737 / LS1520 (496.38) $1,489.14 27202093 HB BALLOON ACL BC0724A $750.00 27202200 HB CATH ELS D97120F5 SWANGANZ $352.26 27202396 HB SYRINGE BOS 5060-05 $478.00 27202486 HB TROCAR APM COR47 $99.00 27202560 HB NEW SET-UP ADULT HEMODIALYSIS $160.00 27202622 HB SHEAR ETH ESFC9 HARMONIC $3,032.78 27202675 HB POWDER MHP SM0007-USA $645.00 27202706 HB SYSTEM ADL 301-5400 SMOKE EVAC $236.00 27202759 HB CATH ARR AB-19608K $536.00 27202760 HB SUTURE SUS RA-1065Q $60.10 27202762 HB DRESSING MOL 395790 $70.22 27202780 HB SHEATH TER ALL RSSXXX PINNACLE (8.50) $29.00 27202784 HB GUIDEWIRE ABB 12776-01 PROWATE $510.00 27202870 HB SUTURE ARX AR7200 $55.50 27202921 HB CATH ARR ASK-05501-USC KIT $414.00 27202942 HB CRRT OR SHIFT TX SET-UP $5,606.00 27203172 HB CATH BOS H749391240845 QUANTUM APEX 4.5 X 8MM BALLOON $560.00 27203339 HB STAPLER J&J PSE45A $888.77 27203383 HB CATH ABB ALL 10124XX-XX TREK $900.00 27203409 HB CATH ABB C408646 DRAGONFLY OPTIS KIT $3,584.00 27203515 HB REAMER ARX ALL AR-14XXLP $874.00 27203618 HB SNARE BOS M00562551/M00562531 $96.00 27203798 HB CATH ARR ALL CS-15XX2-VSP $884.94 27203833 HB BALLOON ABB 1012447-06 TREK $750.00 27203901 HB DRILL GUIDE COC 93363 $607.50 27203944 HB CATH MED ALL 2AF2X4 ADVANCE (4500) $13,500.00 27204066 HB DERMABOND ETH DNX12 TOPICAL SKIN ADHESIVE $79.00 27204181 HB CHARGER STJ 3730ANS $4,416.00 27204202 HB INTRODUCER MED KPX153PB-CDS ONE TIME USE $10,350.00 27204245 HB CATH OLY MAJ-1351 BALLOON DILATION $51.55 27204256 HB CATH MED ALL NCEUPXXXXXX (140) $3,075.00 27204321 HB SYRINGE BOS M00566001 RAPID REFIL SYSTEM $246.00 27204544 HB CATH MED ALL ADM0X00XXX3P (1490) ADMIRAL $3,750.00 27204575 HB TROCAR ARX AR-1934-24DS $48.00 27204585 HB TROCAR APP CFF01 $270.00 27204784 HB NEEDLE ARX AR-12990N/AR16991N SCORPION $585.00 27204835 HB ELECTRODE BOS 3501 EMBLEM $12,000.00 27205075 HB SUTURE ARX AR-7276T LABRALTAPE 1.5MM 3IN $210.00 27205167 HB SLEEVE APP CFS02 FIXATION EXTERNAL $24.00 27205188 HB CATH BBM 33540 EPIDURAL $21.11 27205511 HB BASKET BOS M00546550 $1,485.00 27205532 HB CLOSURE ZLM PS1160 $240.00 27205584 HB DRIVER WRI 57S02020 / 57S02025 $815.00 27205585 HB DRILL BIT WRI 57S00022 / 57S00030 $1,030.00 27205604 HB PROSTEP WRI 57S100MT MICA TRANSLATOR $614.00 27205656 HB CATH MED ALL AB35W0XXXX135 $1,008.00 27205756 HB KWIRE WRI DSDS1014S 1.4MM X 150MM L $100.00 27205805 HB SOCKET ARX AR-4505 PORTAL SKID $135.00 27205851 HB POWERBOX WRI 5770POWER NSK $1,770.00 27206004 HB SCOPE AUR MBR-000011 SINGLE USE MONARCH BRONCHOSCOPE $5,959.00 27206005 HB INTRODUCER AUR MBR-000017 BRONCHOSCOPE KIT $282.00 27206006 HB BRUSH AUR MBR-000015 CYTOLOGY $329.00 27206122 HB DRILL ARX AR-8943-112 $400.00 27240005 HB CATH URETERAL 1 $1,557.00 27240006 HB CATH URETERAL 2 $3,440.00 27240043 HB OTH STER SUPP LVL 1 $77.00 27240044 HB OTH STER SUPP LVL 16 $61,715.00 27240045 HB DRILL BIT/BLADE LVL1 $438.00 27240046 HB DRILL BIT/BLADE LVL2 $1,041.50 27240047 HB DRILL BIT/BLADE LVL3 $2,330.00 27240048 HB DRILL BIT/BLADE LVL4 $3,024.50 27240049 HB DRILL BIT/BLADE LVL5 $5,040.00 27240050 HB DRILL BIT/BLADE LVL6 $7,056.50 27240051 HB DRILL BIT/BLADE LVL7 $9,072.50 27240052 HB DRILL BIT/BLADE LVL8 $16,319.00 27240053 HB DRILL BIT/BLADE LVL9 $20,939.00 27240054 HB SUTURE LEVEL 3 $959.00 27240055 HB SUTURE LEVEL 4 $2,051.50 27240056 HB SUTURE LEVEL 5 $4,693.00 27240057 HB SUTURE LEVEL 6 $3,419.00 27240058 HB SUTURE LEVEL 7 $4,786.50 27240059 HB SUTURE LEVEL 9 $15,429.00 27240060 HB STAPLER/RELOAD 1 $685.00 27240061 HB STAPLER/RELOAD 2 $2,051.50 27240062 HB STAPLER/RELOAD 3 $3,529.50 27240063 HB STAPLER/RELOAD 4 $6,553.50 27240064 HB STAPLER/RELOAD 5 $10,080.00 27240065 HB STAPLER/RELOAD 6 $13,587.50 27240066 HB NEEDLES 2 $1,232.50 27240067 HB NEEDLES 3 $4,196.50 27240068 HB NEEDLES 4 $7,864.50 27240069 HB OTH STER SUPP LVL 2 $1,056.00 27240070 HB OTH STER SUPP LVL 3 $1,582.00 27240071 HB OTH STER SUPP LVL 4 $2,110.00 27240072 HB OTH STER SUPP LVL 5 $1,945.00 27240073 HB OTH STER SUPP LVL 6 $2,333.00 27240074 HB OTH STER SUPP LVL 7 $2,723.00 27240075 HB OTH STER SUPP LVL 8 $3,111.00 27240076 HB OTH STER SUPP LVL 9 $4,668.00 27240077 HB OTH STER SUPP LVL 10 $6,223.00 27240078 HB OTH STER SUPP LVL 11 $7,779.00 27240079 HB OTH STER SUPP LVL 12 $15,557.00 27240080 HB OTH STER SUPP LVL 13 $18,279.00 27240081 HB OTH STER SUPP LVL 14 $30,084.00 27240082 HB OTH STER SUPP LVL 15 $50,140.00 27240083 HB TUBE DRAIN CATH 3 $738.00 27240084 HB TUBE DRAIN CATH 4 $1,319.00 27240085 HB TUBE DRAIN CATH 5 $1,847.00 27240086 HB TUBE DRAIN CATH 6 $8,557.00 27241052 HB CATH CAR 8888570549 DRAIN $13.44 27241053 HB DRAIN AUM 2002-000 CHEST $78.63 27241076 HB CATH BOS M004200624S0 $105.00 27241077 HB CATH BOS M0042011010 $1,152.00 27241078 HB CATH BOS H749518050 $1,896.00 27241079 HB CATH JJH D7T20282CT $3,420.00 27241080 HB CATH COV SD300LG NVG EDG $2,596.32 27241081 HB NEEDLE ARG 253030 BRST LOC $60.00 27241082 HB NEEDLE ARG 253125 BRST LOC $66.00 27241083 HB NEEDLE ART 253100 BRST LOC $84.00 27241084 HB MARKER DEV STAR1401 BRST $236.16 27241087 HB CATH BAR LX35130560 $3,600.00 27241088 HB CATH BAR LX351306100 $3,600.00 27241089 HB CATH BAR LX35130660 $3,600.00 27241090 HB CATH BAR LX351304100 BALLOON $3,900.00 27241091 HB CATH BAR LX35130440 BALLOON $3,900.00 27241092 HB CATH BAR LX351305100 BALLOON $3,900.00 27241093 HB CATH BAR LX35130540 BALLOON $3,900.00 27241094 HB CATH BAR LX35130640 BALLOON $3,900.00 27241095 HB CATH BAR LX35130460 BALLOON $4,650.00 27241096 HB CATH BAR LX35130480 BALLOON $4,650.00 27241097 HB CATH BAR LX351304150 BALLOON $4,725.00 27241098 HB CATH BAR LX351306150 BALLOON $4,725.00 27241099 HB CATH BAR LX351305150 BALLOON $4,800.00 27241100 HB CATH BOS M001175000 BALLOON $598.08 27241101 HB NEEDLE ARG 252075 $74.40 27241105 HB PACK MED DYNJCH301A VAGINAL $63.74 27241106 HB PACK MED DYNJCHCS02A C-SECTION $158.11 27241107 HB PACK MED DYNJ41314 D&C $61.91 27241108 HB PACK MED DYNJ41313 ABDOMINAL $119.88 27241109 HB CATHETER COK G14057 70CM 5 FR 14FR $31.55 27241110 HB CATHETER COK G14521 70CM 5FR URETERAL $41.62 27241111 HB CATHETER ALL BOS M005583XX ENDO DILATOR $854.88 27241112 HB TUBE BAR 331 CATH 20FR DRAIN $202.50 27241113 HB SUTURE ETH D9306 RB1 30IN $545.97 27241117 HB SYRINGE BOS M00550601 GAUGE ASSY 60CC $87.60 27241119 HB BLADE STR 2296-003-111 OSC SAW 25MM $92.94 27245015 HB APPLICATOR ETH MS1995 ENDOSCOPIC 34CM SURGIFLO $416.09 27245063 HB
Load more

Recommended publications
  • Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism
    International Journal of Molecular Sciences Review Factor XIII and Fibrin Clot Properties in Acute Venous Thromboembolism Michał Z ˛abczyk 1,2 , Joanna Natorska 1,2 and Anetta Undas 1,2,* 1 John Paul II Hospital, 31-202 Kraków, Poland; [email protected] (M.Z.); [email protected] (J.N.) 2 Institute of Cardiology, Jagiellonian University Medical College, 31-202 Kraków, Poland * Correspondence: [email protected]; Tel.: +48-12-614-30-04; Fax: +48-12-614-21-20 Abstract: Coagulation factor XIII (FXIII) is converted by thrombin into its active form, FXIIIa, which crosslinks fibrin fibers, rendering clots more stable and resistant to degradation. FXIII affects fibrin clot structure and function leading to a more prothrombotic phenotype with denser networks, characterizing patients at risk of venous thromboembolism (VTE). Mechanisms regulating FXIII activation and its impact on fibrin structure in patients with acute VTE encompassing pulmonary embolism (PE) or deep vein thrombosis (DVT) are poorly elucidated. Reduced circulating FXIII levels in acute PE were reported over 20 years ago. Similar observations indicating decreased FXIII plasma activity and antigen levels have been made in acute PE and DVT with their subsequent increase after several weeks since the index event. Plasma fibrin clot proteome analysis confirms that clot-bound FXIII amounts associated with plasma FXIII activity are decreased in acute VTE. Reduced FXIII activity has been associated with impaired clot permeability and hypofibrinolysis in acute PE. The current review presents available studies on the role of FXIII in the modulation of fibrin clot properties during acute PE or DVT and following these events.
    [Show full text]
  • Comparative Proteomic Analysis Revealed Complex Responses To
    www.nature.com/scientificreports OPEN Comparative proteomic analysis revealed complex responses to classical/novel duck reovirus Received: 12 January 2018 Accepted: 20 June 2018 infections in Cairna moschata Published: xx xx xxxx Tao Yun, Jionggang Hua, Weicheng Ye, Bin Yu, Liu Chen, Zheng Ni & Cun Zhang Duck reovirus (DRV) is an typical aquatic bird pathogen belonging to the Orthoreovirus genus of the Reoviridae family. Reovirus causes huge economic losses to the duck industry. Although DRV has been identifed and isolated long ago, the responses of Cairna moschata to classical/novel duck reovirus (CDRV/NDRV) infections are largely unknown. To investigate the relationship of pathogenesis and immune response, proteomes of C. moschata liver cells under the C/NDRV infections were analyzed, respectively. In total, 5571 proteins were identifed, among which 5015 proteins were quantifed. The diferential expressed proteins (DEPs) between the control and infected liver cells displayed diverse biological functions and subcellular localizations. Among the DEPs, most of the metabolism-related proteins were down-regulated, suggesting a decrease in the basal metabolisms under C/NDRV infections. Several important factors in the complement, coagulation and fbrinolytic systems were signifcantly up-regulated by the C/NDRV infections, indicating that the serine protease-mediated innate immune system might play roles in the responses to the C/NDRV infections. Moreover, a number of molecular chaperones were identifed, and no signifcantly changes in their abundances were observed in the liver cells. Our data may give a comprehensive resource for investigating the regulation mechanism involved in the responses of C. moschata to the C/NDRV infections. Duck reovirus (DRV), a member of the genus Orthoreovirus in the family Reoviridae, is a fatal aquatic bird patho- gen1.
    [Show full text]
  • What Is Optical Imaging?
    What is Optical Imaging? Optical imaging uses light to interrogate cellular and molecular function in the living body, as well as in animal and plant tissue. The information is ultimately derived from tissue composition and biomolecular processes. Images are generated by using photons of light in the wavelength range from ultraviolet to near infrared. Contrast is derived through the use of: exogenous agents (i.e., dyes or probes) that provide a signal endogenous molecules with optical signatures (i.e., NADH, hemoglobin, collagens, etc.) reporter genes. Florescence Imaging Fluorescence protein imaging uses endogenous or exogenous molecules or materials that emit light when activated by an external light source such as a laser. An external light of appropriate wavelength is used to excite a target molecule, which then fluoresces by releasing longer-wavelength, lower-energy light. Fluorescence imaging provides the ability to localize and measure gene expression including normally expressed and aberrant genes, proteins and other pathophysiologic processes. Other potential uses include cell trafficking, tagging superficial structures, detecting lesions and for monitoring tumor growth and response to therapy. Bioluminescent Imaging (BLI) Bioluminescent imaging uses a natural light-emitting protein such as luciferase to trace the movement of certain cells or to identify the location of specific chemical reactions within the body. Bioluminescent imaging is being applied to both gene expression and therapeutic monitoring. Optical Imaging Technologies Near-infrared fluorescence imaging involves imaging fluorescence photons in the near-infrared range (typically 600– 900 nm). A fluorochrome is excited by a lower wavelength, light source and the emitted excitation is recorded as a slightly higher wavelength with a high sensitivity charge-coupled-device (CCD) camera.
    [Show full text]
  • Treatment of Equine Gastric Impaction by Gastrotomy R
    EQUINE VETERINARY EDUCATION / AE / april 2011 169 Case Reporteve_165 169..173 Treatment of equine gastric impaction by gastrotomy R. A. Parker*, E. D. Barr† and P. M. Dixon Dick Vet Equine Hospital, University of Edinburgh, Easter Bush Veterinary Centre, Midlothian; and †Bell Equine Veterinary Clinic, Mereworth, UK. Keywords: horse; colic; gastric impaction; gastrotomy Summary Edinburgh with a deep traumatic shoulder wound of 24 h duration. Examination showed a mildly contaminated, A 6-year-old Warmblood gelding was referred for treatment of 15 cm long wound over the cranial aspect of the left a traumatic shoulder wound and while hospitalised developed scapula that transected the brachiocephalicus muscle a large gastric impaction which was unresponsive to and extended to the jugular groove. The horse was sound medical management. Gastrotomy as a treatment for gastric at the walk and ultrasonography showed no abnormalities impactions is rarely attempted in adult horses due to the of the bicipital bursa. limited surgical access to the stomach. This report describes The wound was debrided and lavaged under standing the successful surgical treatment of the impaction by sedation and partially closed with 2 layers of 3 metric gastrotomy and management of the post operative polyglactin 910 (Vicryl)1 sutures in the musculature and complications encountered. simple interrupted polypropylene (Prolene)1 skin sutures, leaving some ventral wound drainage. Sodium benzyl Introduction penicillin/Crystapen)2 (6 g i.v. q. 8 h), gentamicin (Gentaject)3 (6.6 mg/kg bwt i.v. q. 24 h), flunixin 4 Gastric impactions are rare in horses but, when meglumine (Flunixin) (1.1 mg/kg bwt i.v.
    [Show full text]
  • 15-Coned-Ccrn-Cardiovascular.Pdf
    1 Cardiovascular Introduction A. Anatomy & Physiology B. Cardiac Assessment 1. Cardiac Risk Factors Non Modifiable Age Gender Family History Race Modifiable Smoking Hypertension Diabetes Obesity Stress Exercise Hyperlipidemia 2. Medical & Surgical History 3. Social History 4. Medication History 5. Physical Exam 2 Color Pulses Rate & Rhythm PMI Location Extremity Temperature Dyspnea Fatigue Level Fluid Retention Palpitations Dizziness 6. Chest Pain Exam PQRST Assessment P: Pain, Placement, Provocation Q: Quality (sharp, stabbing, pressure) , Quantity R: Radiation, Relief S: Severity, Systems (nausea, sweaty, dizziness) T: Timing (when it started, how long did it last, what makes it better or worse) C. Diagnostic Tests & Procedures 1. 12 Lead ECG 2. Echocardiography (Transthoracic and Transesepheal) 3. Stress Test 4. Cardiac Catheterization 5. Doppler Ultrasound 6. Blood Work Acute Coronary Syndrome Cardiac Enzymes: CK-MB, Amino Acids: Troponins Heme Proteins: Myoglobin Lipid Profile Triglycerides Cholesterol Low Density Lipoproteins High Density Lipoprotein Coagulation Profile PT/INR aPTT ACT 3 Misc B Type Naturetic Peptide – BNP C Reactive Protein Homocysteine Hemodynamic Monitoring/Assessment CARDIAC OUTPUT HEART RATE X STROKE VOLUME PRELOAD + AFTERLOAD + CONTRACTILITY + The volume of blood in the The pressure or resistance the LV must contract The ability of the against or overcome to eject the blood or create ventricle at end diastole. systole. myocardium to contract. Total Blood Volume
    [Show full text]
  • New York Chapter American College of Physicians Annual
    New York Chapter American College of Physicians Annual Scientific Meeting Poster Presentations Saturday, October 12, 2019 Westchester Hilton Hotel 699 Westchester Avenue Rye Brook, NY New York Chapter American College of Physicians Annual Scientific Meeting Medical Student Clinical Vignette 1 Medical Student Clinical Vignette Adina Amin Medical Student Jessy Epstein, Miguel Lacayo, Emmanuel Morakinyo Touro College of Osteopathic Medicine A Series of Unfortunate Events - A Rare Presentation of Thoracic Outlet Syndrome Venous thoracic outlet syndrome, formerly known as Paget-Schroetter Syndrome, is a condition characterized by spontaneous deep vein thrombosis of the upper extremity. It is a very rare syndrome resulting from anatomical abnormalities of the thoracic outlet, causing thrombosis of the deep veins draining the upper extremity. This disease is also called “effort thrombosis― because of increased association with vigorous and repetitive upper extremity activities. Symptoms include severe upper extremity pain and swelling after strenuous activity. A 31-year-old female with a history of vascular thoracic outlet syndrome, two prior thrombectomies, and right first rib resection presented with symptoms of loss of blood sensation, dull pain in the area, and sharp pain when coughing/sneezing. When the patient had her first blood clot, physical exam was notable for swelling, venous distension, and skin discoloration. The patient had her first thrombectomy in her right upper extremity a couple weeks after the first clot was discovered. Thrombolysis with TPA was initiated, and percutaneous mechanical thrombectomy with angioplasty of the axillary and subclavian veins was performed. Almost immediately after the thrombectomy, the patient had a rethrombosis which was confirmed by ultrasound.
    [Show full text]
  • Colorectal Cancer Screening
    CLINICAL MEDICAL POLICY Policy Name: Colorectal Cancer Screening Policy Number: MP-059-MD-PA Responsible Department(s): Medical Management Provider Notice Date: 03/19/2021 Issue Date: 03/19/2021 Effective Date: 04/19/2021 Next Annual Review: 02/2022 Revision Date: 02/17/2021 Products: Gateway Health℠ Medicaid Application: All participating hospitals and providers Page Number(s): 1 of 10 DISCLAIMER Gateway Health℠ (Gateway) medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions. POLICY STATEMENT Gateway Health℠ may provide coverage under the medical-surgical benefits of the Company’s Medicaid products for medically necessary colorectal cancer screening procedures. This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness or condition. Each person’s unique clinical circumstances warrant individual consideration, based upon review of applicable medical records. (Current applicable Pennsylvania HealthChoices Agreement Section V. Program Requirements, B. Prior Authorization of Services, 1. General Prior Authorization Requirements.) Policy No. MP-059-MD-PA Page 1 of 10 DEFINITIONS Average-Risk Population – Patient population defined as having no personal history of adenomatous polyps, colorectal cancer, or inflammatory bowel disease (Crohn’s disease and Ulcerative Colitis); no family history of colorectal cancer or adenomatous polyps, familial adenomatous polyposis, or hereditary nonpolyposis colorectal cancer. High-Risk Population – Patient population defined as having a first-degree relative (sibling, parent, or child) who has had colorectal cancer or adenomatous polyps; OR family history of familial adenomatous polyposis; OR family history of hereditary non-polyposis colorectal cancer; OR family history of MYH- associated polyposis in siblings; OR diagnosis of Cowden syndrome.
    [Show full text]
  • Role of Cornification and Triglyceride Synthesis Genes
    Gillespie et al. BMC Genomics 2013, 14:169 http://www.biomedcentral.com/1471-2164/14/169 RESEARCH ARTICLE Open Access Transcriptome analysis of pigeon milk production – role of cornification and triglyceride synthesis genes Meagan J Gillespie1,2*, Tamsyn M Crowley1,3, Volker R Haring1, Susanne L Wilson1, Jennifer A Harper1, Jean S Payne1, Diane Green1, Paul Monaghan1, John A Donald2, Kevin R Nicholas3 and Robert J Moore1 Abstract Background: The pigeon crop is specially adapted to produce milk that is fed to newly hatched young. The process of pigeon milk production begins when the germinal cell layer of the crop rapidly proliferates in response to prolactin, which results in a mass of epithelial cells that are sloughed from the crop and regurgitated to the young. We proposed that the evolution of pigeon milk built upon the ability of avian keratinocytes to accumulate intracellular neutral lipids during the cornification of the epidermis. However, this cornification process in the pigeon crop has not been characterised. Results: We identified the epidermal differentiation complex in the draft pigeon genome scaffold and found that, like the chicken, it contained beta-keratin genes. These beta-keratin genes can be classified, based on sequence similarity, into several clusters including feather, scale and claw keratins. The cornified cells of the pigeon crop express several cornification-associated genes including cornulin, S100-A9 and A16-like, transglutaminase 6-like and the pigeon ‘lactating’ crop-specific annexin cp35. Beta-keratins play an important role in ‘lactating’ crop, with several claw and scale keratins up-regulated. Additionally, transglutaminase 5 and differential splice variants of transglutaminase 4 are up-regulated along with S100-A10.
    [Show full text]
  • Identification of Intracellular Factor XIII in Human Monocytes and Macrophages
    Identification of Intracellular Factor XIII in Human Monocytes and Macrophages Per Henriksson, Susanne Becker, Garry Lynch, and Jan McDonagh Department of Pediatrics, and Blood Coagulation Laboratory, University of Lund, General Hospital, Malmd, Sweden; Department of Obstetrics and Gynecology, University ofNorth Carolina, Chapel Hill, North Carolina 27514; Department ofPathology, Beth Israel Hospital and Harvard Medical School, and Charles A. Dana Research Institute, Boston, Massachusetts 02215 Abstract transglutaminases have been identified, of which the most well characterized are tissue transglutaminase and Factor XIIIa. A Factor XIII is a blood protransglutaminase that is distributed tissue transglutaminase, which may be present in many cell in plasma and platelets. The extracellular and intracellular types, is usually isolated from liver or erythrocytes (1). It is a zymogenic forms differ in that the plasma zymogen contains A monomeric protein (relative molecular weight [Mn' - 75,000- and B subunits, while the platelet zymogen has A subunits 80,000) which has only been detected as an active enzyme; no only. Both zymogens form the same enzyme. Erythrocytes, in zymogen has been found (2-4). Factor XIIIa, the blood contrast, contain a tissue transglutaminase that is distinct from coagulation enzyme that was first found to catalyze the covalent Factor XIII. In this study other bone marrow-derived cells stabilization of fibrin, exists in two zymogenic forms. Extra- were examined for transglutaminase activity. Criteria that were cellular or plasma Factor XIII is a noncovalently associated used to differentiate Factor XIII proteins from erythrocyte tetramer (MW- 320,000), consisting of two A and two B transglutaminase included: (a) immunochemical and immuno- subunits; intracellular Factor XIII is a dimer (Mr - 150,000) histochemical identification with monospecific polyclonal and of A subunits.
    [Show full text]
  • Factor XIII Deficiency
    Haemophilia (2008), 14, 1190–1200 DOI: 10.1111/j.1365-2516.2008.01857.x ORIGINAL ARTICLE Factor XIII deficiency L. HSIEH and D. NUGENT Division of Hematology, ChildrenÕs Hospital of Orange County, Orange, CA, USA Summary. Inherited factor XIII (FXIII) deficiency is been more than 60 FXIII mutations identified in the a rare bleeding disorder that can present with current literature. In addition, single nucleotide umbilical bleeding during the neonatal period, polymorphisms have been described, some of which delayed soft tissue bruising, mucosal bleeding and have been shown to affect FXIII activity, contribut- life-threatening intracranial haemorrhage. FXIII defi- ing further to the heterogeneity in patient presenta- ciency has also been associated with poor wound tion and severity of clinical symptoms. Although healing and recurrent miscarriages. FXIII plays an there is a lifelong risk of bleeding, the prognosis is integral role in haemostasis by catalysing the cross- excellent when current prophylactic treatment is linking of fibrin, platelet membrane and matrix available using cryoprecipitate or plasma-derived proteins throughout thrombus formation, thus sta- FXIII concentrate. bilizing the blood clot. The molecular basis of FXIII deficiency is characterized by a high degree of Keywords: bleeding disorders, coagulation, factor heterogeneity, which contributes to the different XIII, factor XIII deficiency, fibrin stabilizing factor, clinical manifestations of the disease. There have protransglutaminase clear that intracellular FXIII, especially in platelet Introduction and vascular bed may play an equally important role Prior to delving into the clinical and biochemical in haemostasis. details which characterize this fascinating clotting In plasma, FXIII circulates as a pro-transglutamin- factor, it is worth taking a moment to consider this ase (FXIII-A2B2) composed of two catalytic A important fact: factor XIII (FXIII) is not just another subunits (FXIII-A2) and two non-catalytic B subunits plasma protein in the clotting cascade.
    [Show full text]
  • Anti-Inflammatory Role of Curcumin in LPS Treated A549 Cells at Global Proteome Level and on Mycobacterial Infection
    Anti-inflammatory Role of Curcumin in LPS Treated A549 cells at Global Proteome level and on Mycobacterial infection. Suchita Singh1,+, Rakesh Arya2,3,+, Rhishikesh R Bargaje1, Mrinal Kumar Das2,4, Subia Akram2, Hossain Md. Faruquee2,5, Rajendra Kumar Behera3, Ranjan Kumar Nanda2,*, Anurag Agrawal1 1Center of Excellence for Translational Research in Asthma and Lung Disease, CSIR- Institute of Genomics and Integrative Biology, New Delhi, 110025, India. 2Translational Health Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. 3School of Life Sciences, Sambalpur University, Jyoti Vihar, Sambalpur, Orissa, 768019, India. 4Department of Respiratory Sciences, #211, Maurice Shock Building, University of Leicester, LE1 9HN 5Department of Biotechnology and Genetic Engineering, Islamic University, Kushtia- 7003, Bangladesh. +Contributed equally for this work. S-1 70 G1 S 60 G2/M 50 40 30 % of cells 20 10 0 CURI LPSI LPSCUR Figure S1: Effect of curcumin and/or LPS treatment on A549 cell viability A549 cells were treated with curcumin (10 µM) and/or LPS or 1 µg/ml for the indicated times and after fixation were stained with propidium iodide and Annexin V-FITC. The DNA contents were determined by flow cytometry to calculate percentage of cells present in each phase of the cell cycle (G1, S and G2/M) using Flowing analysis software. S-2 Figure S2: Total proteins identified in all the three experiments and their distribution betwee curcumin and/or LPS treated conditions. The proteins showing differential expressions (log2 fold change≥2) in these experiments were presented in the venn diagram and certain number of proteins are common in all three experiments.
    [Show full text]
  • Geisinger Lewistown Hospital Published: March 25, 2019
    Geisinger Lewistown Hospital Published: March 25, 2019 DESCRIPTION CHARGE Fine needle aspiration; without imaging guidance $ 607.00 Fine needle aspiration; without imaging guidance $ 286.00 Fine needle aspiration; with imaging guidance $ 2,218.00 Fine needle aspiration; with imaging guidance $ 1,691.00 Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; first lesion $ 1,979.00 Placement of soft tissue localization device(s) (eg, clip, metallic pellet, wire/needle, radioactive seeds), percutaneous, including imaging guidance; each $ 1,385.00 additional lesion (List separately in addition to code for primary procedure) Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); simple or single $ 657.00 Incision and drainage of abscess (eg, carbuncle, suppurative hidradenitis, cutaneous or subcutaneous abscess, cyst, furuncle, or paronychia); complicated or $ 986.00 multiple Incision and drainage of pilonidal cyst; simple $ 657.00 Incision and drainage of pilonidal cyst; complicated $ 3,726.00 Incision and removal of foreign body, subcutaneous tissues; simple $ 1,694.00 Incision and removal of foreign body, subcutaneous tissues; complicated $ 4,710.00 Incision and drainage of hematoma, seroma or fluid collection $ 3,470.00 Puncture aspiration of abscess, hematoma, bulla, or cyst $ 1,272.00 Puncture aspiration of abscess, hematoma, bulla, or cyst $ 657.00 Incision
    [Show full text]